Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev Thread | Prev | Next | Next Thread
Author: TMFTwitty Big funky green star, 20000 posts Old School Fool CAPS All Star Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 138  
Subject: Bad, Bad Baxter Date: 12/23/2003 4:25 PM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 0
http://www.fool.com/News/mft/2003/mft03122311.htm?ref=btp

Bad, Bad Baxter

By Jeff Hwang
December 23, 2003

Shares of Baxter International (NYSE: BAX) were down 6% to $29 after the latest in a series of earnings warnings this year that have shaken investor confidence.

This morning, the medical products company said fourth-quarter earnings from continuing operations would come in between $0.62 and $0.65 per share, resulting in full-year earnings from continuing operations in the range of $1.52 to $1.55 per share. Back in October, the company had forecasted fourth-quarter earnings of $0.75 to $0.85 per share and reiterated full-year earnings of $1.65 to $1.75 per share.

Full-year 2003 sales growth will still be in the 8%-10% range due to positive growth trends for its recombinant factor VIII and medication delivery products. Baxter also expects gross margins to rise sequentially from the third quarter. However, earnings will be reduced by an "unfavorable geographic mix" and a lower-than-expected gain from the sale of the company's investment in Acambis (Nasdaq: ACAM), a U.K.-based vaccine developer. A gain of $0.03 per share from that sale is included in the company's forecast.

At the beginning of 2003, Baxter had forecast full-year earnings of $2.22 to $2.29 per share. But slow sales and intense competition for its blood plasma products caused the company to lower its estimates in March. As a result, the stock fell from near its current level to under $20 per share. Then in July, the company lowered its outlook again to between $1.65 and $1.75 per share, taking a $0.33-per-share restructuring charge.

The stock had since rebounded on hopes for Advate, Baxter's new hemophilia treatment. However, a weaker-than-expected third-quarter report put an end to that, and today's warning does not help.

Baxter's frequent earnings warnings put a serious question mark on the credibility of its management's forecasts. You almost have to wonder why they even bother to give them in the first place. Expect continued pressure on Baxter's stock until the company's management can gain some level of consistency.

Discuss busted forecasts on the Baxter discussion board -- only at Fool.com. Jeff Hwang can be reached at JHwang@fool.com.
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev Thread | Prev | Next | Next Thread

Announcements

2013 Feste Award Voting Begins!
Who will win the 2013 Feste Award? Vote now for the Fool that most exemplifies the Fool Community mission of Learning Together!
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Post of the Day:
Tax Strategies

TMFPMarti-Feeling Good
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement